Topical peptide eye drop promising for wet age-related macular degeneration
NEW ORLEANS — In this video, David Almeida, MD, MBA, PhD, discusses the safety, tolerability and pharmacodynamic signal of CG-P5, a topical peptide eye drop, in patients with wet age-related macular degeneration.
Almeida, of Erie Retina Research in Pennsylvania, said that up to 40% of patients being treated for wet AMD do not meet treatment expectations.
In a phase 1 study presented at the American Academy of Ophthalmology meeting, patients with treatment-experienced wet AMD were randomly assigned to receive CG-P5 (Caregen), Eylea (aflibercept 2 mg, Regeneron) or placebo for 84 days.